IL282424A - Alk2 antibodies and methods of use thereof - Google Patents
Alk2 antibodies and methods of use thereofInfo
- Publication number
- IL282424A IL282424A IL282424A IL28242421A IL282424A IL 282424 A IL282424 A IL 282424A IL 282424 A IL282424 A IL 282424A IL 28242421 A IL28242421 A IL 28242421A IL 282424 A IL282424 A IL 282424A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- alk2 antibodies
- alk2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749463P | 2018-10-23 | 2018-10-23 | |
| PCT/US2019/057679 WO2020086730A1 (en) | 2018-10-23 | 2019-10-23 | Alk2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL282424A true IL282424A (en) | 2021-06-30 |
Family
ID=70331231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282424A IL282424A (en) | 2018-10-23 | 2021-04-19 | Alk2 antibodies and methods of use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12331124B2 (https=) |
| EP (1) | EP3870613A4 (https=) |
| JP (2) | JP7512272B2 (https=) |
| KR (1) | KR102919834B1 (https=) |
| CN (2) | CN113366019B (https=) |
| AU (1) | AU2019364415A1 (https=) |
| BR (1) | BR112021007660A2 (https=) |
| CA (1) | CA3116900A1 (https=) |
| IL (1) | IL282424A (https=) |
| WO (1) | WO2020086730A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3870181B1 (en) | 2018-10-26 | 2024-08-14 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20220140802A (ko) | 2020-02-11 | 2022-10-18 | 리제너론 파아마슈티컬스, 인크. | 항-acvr1 항체 및 이의 용도 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| US20250282877A1 (en) * | 2021-05-11 | 2025-09-11 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
| US20250034148A1 (en) * | 2021-11-02 | 2025-01-30 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
| WO2024092133A1 (en) * | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2570458C (en) * | 2004-06-09 | 2014-05-20 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
| CA2662350A1 (en) | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| JP5755635B2 (ja) | 2009-03-30 | 2015-07-29 | アクセルロン ファーマ， インコーポレイテッド | Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用 |
| WO2011116212A2 (en) | 2010-03-17 | 2011-09-22 | Oncomed Pharmaceuticals, Inc. | Bone morphogenetic protein receptor binding agents and methods of their use |
| WO2012065059A2 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Treatment of atherosclerosis with bmp-alk3 antagonists |
| JP6601687B2 (ja) * | 2014-03-31 | 2019-11-06 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| TWI703156B (zh) * | 2015-01-30 | 2020-09-01 | 學校法人埼玉醫科大學 | 抗ａｌｋ２抗體 |
| WO2016154572A1 (en) * | 2015-03-26 | 2016-09-29 | Vanderbilt University | Antibody-mediated neutralizaton of ebolaviruses |
| WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| KR20220140802A (ko) | 2020-02-11 | 2022-10-18 | 리제너론 파아마슈티컬스, 인크. | 항-acvr1 항체 및 이의 용도 |
| WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2022098821A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating lymphopenia |
| WO2022099166A1 (en) | 2020-11-09 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating cardiovascular-related disease |
| US20250282877A1 (en) | 2021-05-11 | 2025-09-11 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
-
2019
- 2019-10-23 CN CN201980085459.7A patent/CN113366019B/zh active Active
- 2019-10-23 WO PCT/US2019/057679 patent/WO2020086730A1/en not_active Ceased
- 2019-10-23 BR BR112021007660-3A patent/BR112021007660A2/pt unknown
- 2019-10-23 AU AU2019364415A patent/AU2019364415A1/en active Pending
- 2019-10-23 KR KR1020217015329A patent/KR102919834B1/ko active Active
- 2019-10-23 CA CA3116900A patent/CA3116900A1/en active Pending
- 2019-10-23 CN CN202411099364.XA patent/CN118955715A/zh active Pending
- 2019-10-23 EP EP19877108.1A patent/EP3870613A4/en active Pending
- 2019-10-23 JP JP2021521976A patent/JP7512272B2/ja active Active
-
2021
- 2021-04-19 IL IL282424A patent/IL282424A/en unknown
- 2021-04-22 US US17/237,240 patent/US12331124B2/en active Active
-
2024
- 2024-06-26 JP JP2024102779A patent/JP2024114820A/ja active Pending
-
2025
- 2025-05-14 US US19/207,888 patent/US20250270333A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022505585A (ja) | 2022-01-14 |
| US20250270333A1 (en) | 2025-08-28 |
| CA3116900A1 (en) | 2020-04-30 |
| WO2020086730A1 (en) | 2020-04-30 |
| EP3870613A1 (en) | 2021-09-01 |
| EP3870613A4 (en) | 2022-08-03 |
| CN113366019A (zh) | 2021-09-07 |
| BR112021007660A2 (pt) | 2021-08-03 |
| JP2024114820A (ja) | 2024-08-23 |
| CN113366019B (zh) | 2024-08-27 |
| CN118955715A (zh) | 2024-11-15 |
| JP7512272B2 (ja) | 2024-07-08 |
| KR102919834B1 (ko) | 2026-01-30 |
| US12331124B2 (en) | 2025-06-17 |
| AU2019364415A1 (en) | 2021-05-20 |
| KR20210088591A (ko) | 2021-07-14 |
| US20210253720A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282424A (en) | Alk2 antibodies and methods of use thereof | |
| PL3601358T3 (pl) | Przeciwciała anty-trem2 i sposoby ich wykorzystania | |
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
| PL3551660T3 (pl) | Przeciwciała anty-ctla-4 i sposoby ich stosowania | |
| IL259713A (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL264528B1 (en) | Fcrn antibodies and methods of use thereof | |
| IL286208A (en) | Humanized influenza monoclonal antibodies and methods of use thereof | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| IL263657A (en) | Anti-c5 antibodies and methods of use | |
| DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
| IL269074A (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL287039A (en) | Cd19 antibodies and methods of using the same | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| IL286641A (en) | Engineered iga antibodies and methods of use | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL283136A (en) | Antibodies to mucin-16 and methods of use thereof | |
| EP3630046C0 (en) | ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USE THEREOF | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them |